Ligand Pharmaceuticals, Inc.

Ligand Pharmaceuticals, Inc.

LGNXZ - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$59.89K
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Ligand Pharmaceuticals, Inc.Ligand Pharmaceuticals, Inc.119.2-2%-1.2
$61.80

Current Fair Value

2060023.3% upside

Undervalued by 2060023.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$59,886.00
Enterprise Value$1.10 Billion
Earnings per Share$6.44
Beta0.98
Outstanding Shares19,962,000

Return

Return on Equity2.10%ROE
Return on Assets0.90%
Return on Invested Capital7.06%

Valuation & Multiples

P/E Ratio119.22P/E Ratio
PEG-75.88PEG
Price to Sales0.0Price to Sales
Price to Book Ratio0.0Price to Book Ratio
Enterprise Value to Revenue4.33
Enterprise Value to EBIT8.95
Enterprise Value to Net Income54
Total Debt to Enterprise1.05
Debt to Equity1.2Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 29, 2026
EPS
$2.67
Est. $2.33
Revenue
$78.75 M
Est. $77.00 M

Next Earnings Call

Expected Date
March 4, 2027
EPS Estimate
$2.88
Consensus analyst estimate
Revenue Estimate
$97.80 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Ligand Pharmaceuticals, Inc.

47 employees
CEO: John Higgins

Ligand Pharmaceuticals, Inc. functions as a biopharmaceutical firm, primarily focusing on developing and acquiring innovative technologies that empower other pharmaceutical companies in their drug discovery and development processes. Its...

Questions & Answers